DB00948ApprovedSmall molecule
Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.
- Mechanism
- Curator reviewed
By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, mezlocillin inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins; it is possible that mezlocillin interferes with an autolysin inhibitor.
- Primary indication
- Used to treat serious gram–negative infections of the lungs, urinary tract, and skin.Curator reviewed
- Formula / weight
- C21H25N5O8S2 · 539.582 g/mol (avg)
- Code names
- BAY-F-1353
Resolves to
Clinical / RWD
Structure
InChIKey
YPBATNHYBCGSSN-VWPFQQQWSA-NSMILES[H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)[C@H](NC(=O)N1CCN(C1=O)S(C)(=O)=O)C1=CC=CC=C1)C(O)=OWhat you can answer from here — as of September 14, 2026
5Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Mezlocillin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account